180 Life Sciences Corp (ATNF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 180 Life Sciences Corp (ATNF) has a cash flow conversion efficiency ratio of -0.037x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.30 Million) by net assets ($445.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 180 Life Sciences Corp (ATNF) market capitalisation for the company's overall valuation and market capitalisation.
180 Life Sciences Corp - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how 180 Life Sciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
180 Life Sciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 180 Life Sciences Corp ranked by their cash flow conversion efficiency. Explore earnings quality score of 180 Life Sciences Corp to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cansino Biologics Inc
SHG:688185
|
0.003x |
|
Siam Global House Public Company Limited
BK:GLOBAL
|
0.245x |
|
Jubilant Ingrevia Limited
NSE:JUBLINGREA
|
0.032x |
|
Asseco South Eastern Europe S.A.
WAR:ASE
|
0.038x |
|
MAP Aktif Adiperkasa Tbk PT
JK:MAPA
|
0.093x |
|
Indian Energy Exchange Limited
NSE:IEX
|
-0.006x |
|
Kunshan Huguang Auto Harness Co Ltd
SHG:605333
|
0.023x |
|
SINOPEC Engineering (Group) Co. Ltd
F:1NS
|
-0.016x |
Annual Cash Flow Conversion Efficiency for 180 Life Sciences Corp (2017–2024)
The table below shows the annual cash flow conversion efficiency of 180 Life Sciences Corp from 2017 to 2024. View 180 Life Sciences Corp stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.25 Million | $-1.48 Million | -0.160x | -100.19% |
| 2023-12-31 | $-127.73K | $-10.92 Million | 85.508x | +8098.28% |
| 2022-12-31 | $11.34 Million | $-12.13 Million | -1.069x | -985.73% |
| 2021-12-31 | $39.32 Million | $-3.87 Million | -0.098x | +22.98% |
| 2020-12-31 | $30.29 Million | $-3.87 Million | -0.128x | -48.58% |
| 2019-12-31 | $38.57 Million | $-3.32 Million | -0.086x | -183.69% |
| 2018-12-31 | $-7.68 Million | $-789.23K | 0.103x | +2432.13% |
| 2017-12-31 | $112.83 Million | $-497.36K | -0.004x | -- |
About 180 Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more